ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

    Published Apr 7, 2025

    T

    Tara Graff, MD

    Medical Professional

    Mosun-SQ data

    Related Videos
    Dr. Himisha Beltran reviews the data in PARP inhibitors for BRCA2 mutations in prostate cancer (Video 2/3)

    Dr. Himisha Beltran reviews the data in PARP inhibitors for BRCA2 mutations in prostate cancer (Video 2/3)

    Himisha Beltran, MD
    Dr. Amer Zeidan reviews the data in luspatercept for lower-risk MDS including outcomes and OS (Video 2/3)

    Dr. Amer Zeidan reviews the data in luspatercept for lower-risk MDS including outcomes and OS (Video 2/3)

    Amer Zeidan, MD
    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    Martin Dietrich
    Dr. Edgardo Santos discusses the emergence of SQ amivantamab+lazertinib in 1L EGFRm mNSCLC (Video 1/3)

    Dr. Edgardo Santos discusses the emergence of SQ amivantamab+lazertinib in 1L EGFRm mNSCLC (Video 1/3)

    Edgardo Santos, MD
    Dr. Manali Kamdar discusses the curative potential of 2L CAR-T with liso-cel in R/R LBCL (Video 1/3)

    Dr. Manali Kamdar discusses the curative potential of 2L CAR-T with liso-cel in R/R LBCL (Video 1/3)

    Manali Kamdar, MD
    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    Joshua Reuss, MD